This effect also appeared to translate to ADHR patients, where a case is reported with a cessation of symptomatology after IV iron administration, and in a clinical trial where iron supplementation reduced iFGF23 levels and hypophosphatemia [107]. The gene discussed is FGF23; the disease is hypophosphatemia.